Quite often, nurse leaders are faced with ethical dilemmas, such as those associated with choices between competing needs and limited resources. Resources are finite, and competition for those resources occurs daily in all organizations.
For example, the use of 12-hour shifts has been a strategy to retain nurses. However, evidence suggests that as nurses work more hours in a shift, they commit more errors. How do effective leaders find a balance between the needs of the organization and the needs of ensuring quality, effective, and safe patient care?
reflect on a national healthcare issue and examine how competing needs may impact the development of polices to address that issue.
• Review the Resources and think about the national healthcare issue/stressor you previously selected (Rising Healthcare Costs as a Deterrent to Quality Healthcare).
• Reflect on the competing needs in healthcare delivery as they pertain to the national healthcare issue/stressor you previously examined (Rising Healthcare Costs as a Deterrent to Quality Healthcare)
Write an explanation of how competing needs, such as the needs of the workforce, resources, and patients, may impact the development of policy.
Then, describe any specific competing needs that may impact the national healthcare issue/stressor you selected. What are the impacts, and how might policy address these competing needs? Be specific and provide examples.
Human Services to set a benchmark price for clinically comparable drugs that are interchangeable. Though these changes may produce more cost-effective medication, a drawback may be the lack of market diversity. Rather than having one pharmaceutical company dictating the price, the federal government is dictating the price thus creating a lack of competition. Having one body dictate everything may create tensions between pharmaceutical companies and the government; thus, change might not be made at all. Next, pharmaceutical companies spend a substantial amount of money on marketing rather than research. At this point, we are unaware of the exact cost breakdown of pharmaceutical company revenue. There is no requirement for documentation to show the difference between profits, money used for marketing, and money used for research. Often times, marketing costs are categorized into research funds. By enforcing transparency, we may have better insight into the way drug prices are set and can determine whether set prices are justified. For the past 20 years, leading drug companies earned more than 70% of their sales from products they did not develop. More transparency with prices and clinical outcomes would allow physicians, patients, and payers to understand the true value of a treatment. Ultimately, transparency is about ensuring patients have access to the drugs they need, and creating a sustainable, vibrant, and innovative healthcare system for everyone. However as with our previous proposal, we took into consideration potential drawbacks to having drug pricing transparency. If we become stricter with the way finances are reported, pharmaceutical companies may in turn resort to increasing drug prices, leading to an additional rise in costs and spending. If manufacturers are required to disclose drug pricing, the process of gathering and disseminating this information may become time intensive and potentially result in less profitability to the manufacturer (ncbi article). A decrease in profitability may cause a decline in innovation and the desire to conduct innovative research.>GET ANSWER